<DOC>
	<DOCNO>NCT00002494</DOCNO>
	<brief_summary>RATIONALE : Drugs use chemotherapy use different way stop cancer cell divide stop grow die . Combining one drug may kill cancer cell . PURPOSE : Phase II trial study effectiveness combination chemotherapy alternate regimen chemotherapy treat patient non-Hodgkin 's lymphoma acute lymphocytic leukemia .</brief_summary>
	<brief_title>Combination Chemotherapy Treating Patients With Non-Hodgkin 's Lymphoma Acute Lymphocytic Leukemia</brief_title>
	<detailed_description>OBJECTIVES : I . Determine response rate disease free survival HIV seronegative patient diffuse small noncleaved cell lymphoma L3 acute lymphocytic leukemia treat high intensity , brief duration combination chemotherapy : alternating course ifosfamide/cytarabine/etoposide cyclophosphamide/doxorubicin , methotrexate/vincristine/dexamethasone . II . Determine toxicity regimens HIV negative patient . OUTLINE : Patients stratify participate institution disease type ( diffuse small noncleaved cell lymphoma v L3 ALL ) . Patients receive cyclophosphamide IV 5-10 minute day 1 5 oral prednisone day 1 7 , follow alternating course : 2 ) ifosfamide IV 1 hour day 8 12 , methotrexate IV 24 hour day 8 ; leucovorin calcium IV 36 hour initiation methotrexate , IV ( orally tolerate , first 24 hour ) every 6 hour serum methotrexate level 5 x 10 minus eighth M ; vincristine IV day 8 ; cytarabine IV 48 hour etoposide IV 60 minute day 11 12 ; oral dexamethasone day 8 12 , plus triple intrathecal therapy ( TIT ) methotrexate , cytarabine , hydrocortisone day 8 12 , 3 ) cyclophosphamide IV 5-10 minute day 29 33 ; methotrexate IV 24 hour vincristine IV day 29 ; leucovorin calcium IV 36 hour initiation methotrexate , IV ( orally tolerate , first 24 hour ) every 6 hour serum methotrexate level 5 x 10 minus eighth M ; doxorubicin IV day 32 33 ; oral dexamethasone day 29 33 , plus TIT day 29 , dos . Patients CNS disease diagnosis continue TIT weekly CSF clear , weekly 4 week . TIT must complete prior initiation radiotherapy . All patient must complete least first 3 course chemotherapy . Courses 2 3 repeat 3 time absence disease progression unacceptable toxicity . On day 134-139 , patient prior bone marrow involvement receive cranial radiation therapy . Patients achieve less complete response HLA-matched sibling undergo allogeneic bone marrow transplant protocol CLB-9113 . Patients follow monthly 6 month , every 2 month 18 month , every 6 month 2 year , thereafter survival .</detailed_description>
	<mesh_term>Lymphoma</mesh_term>
	<mesh_term>Leukemia</mesh_term>
	<mesh_term>Hydrocortisone 17-butyrate 21-propionate</mesh_term>
	<mesh_term>Cortisol succinate</mesh_term>
	<mesh_term>Hydrocortisone acetate</mesh_term>
	<mesh_term>Dexamethasone</mesh_term>
	<mesh_term>Prednisone</mesh_term>
	<mesh_term>Hydrocortisone</mesh_term>
	<mesh_term>Liposomal doxorubicin</mesh_term>
	<mesh_term>Cyclophosphamide</mesh_term>
	<mesh_term>Methotrexate</mesh_term>
	<mesh_term>Doxorubicin</mesh_term>
	<mesh_term>Etoposide</mesh_term>
	<mesh_term>Cytarabine</mesh_term>
	<mesh_term>Vincristine</mesh_term>
	<mesh_term>Ifosfamide</mesh_term>
	<mesh_term>Levoleucovorin</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Histologically document diffuse small noncleaved cell lymphoma ( category J IWF ) stage Nodal abdominal mass le 25 % lymphoblast marrow define lymphoma OR Histologically document L3 acute lymphocytic leukemia ( ALL ) Greater 25 % lymphoblast marrow define ALL , regardless presence bulky nodal disease Lymphoma requirement include : Documentation lymphadenopathy , splenomegaly , hepatomegaly , presence absence abdominal mass , presence absence B symptom Measurable disease ascites pleural effusion , bony disease , CNS lesions Bidimensionally measurable mass physical exam , xray , CT , MRI OR Clearly define hepatic mass great 3.5 cm CT , MRI , ultrasound consider represent lymphoma OR Histologically document hepatic lymphoma liver extend 5 cm costal margin quiet respiration ALL requirement include : Documentation monoclonal surface immunoglobulin surface immunophenotyping Lymph node biopsy strongly recommend patient obvious marrow involvement Disease label L3 also manifest lymphadenopathy must evaluate lymphoma ( see ) PATIENT CHARACTERISTICS : Age : 15 Performance status : Any status Life expectancy : At least 2 year Hematopoietic : Not specify Hepatic : Bilirubin great 1.5 time normal ( unless elevation directly attributable malignancy ) Renal : Creatinine great 1.5 time normal ( unless elevation directly attributable malignancy ) Cardiovascular : No uncontrolled severe cardiovascular disease , e.g . : No myocardial infarction within past 6 month No congestive heart failure Other : HIV negative No active , uncontrolled bacterial , viral , fungal infection No active , uncontrolled duodenal ulcer No serious medical illness No serious psychiatric condition would preclude informed consent protocol compliance No second malignancy within 5 year except : Curatively treat carcinoma situ cervix Curatively treat basal cell carcinoma Not pregnant Effective contraception require fertile patient PRIOR CONCURRENT THERAPY : Biologic : No concurrent growth factor Chemotherapy : Not specify Endocrine therapy : Not specify Radiotherapy : No concurrent palliative radiotherapy Surgery : Not specify Other : No prior therapy</criteria>
	<gender>All</gender>
	<minimum_age>15 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>June 2016</verification_date>
	<keyword>untreated adult acute lymphoblastic leukemia</keyword>
	<keyword>L3 adult acute lymphoblastic leukemia</keyword>
	<keyword>stage I adult Burkitt lymphoma</keyword>
	<keyword>stage II adult Burkitt lymphoma</keyword>
	<keyword>stage III adult Burkitt lymphoma</keyword>
	<keyword>stage IV adult Burkitt lymphoma</keyword>
	<keyword>contiguous stage II adult Burkitt lymphoma</keyword>
	<keyword>noncontiguous stage II adult Burkitt lymphoma</keyword>
</DOC>